跳至主要内容
临床试验/NCT02323867
NCT02323867进行中(未招募)2 期

UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES

Children's Hospital of Philadelphia2 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2014年10月1日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
140
试验地点
2
主要终点
Engraftment: rates of engraftment, defined as the first day of Absolute Neutrophil Count (ANC) greater than 500 for the first of three consecutive days

研究概览

简要总结

This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and graft versus host disease (GVHD), and one year leukemia free survival.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 23 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Leukemias/lymphomas
  • Acute myeloid leukemia, primary or secondary Disease status: remission or <10% bone marrow blasts
  • Myelodysplasia
  • Acute lymphoblastic leukemia Disease status: in hematologic remission
  • Chronic myelogenous leukemia Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase.
  • Mixed lineage or biphenotypic acute leukemia
  • Lymphoblastic lymphoma Disease status: remission
  • Burkitt's lymphoma/leukemia: Disease status- in remission
  • Acceptable organ status clearance
  • No active untreated infection. Patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic
  • Signed informed consent.
  • Negative pregnancy test for females of childbearing potential.

排除标准

  • Patients who do not meet disease, organ or infectious criteria.
  • No suitable donor
  • Received previous allogeneic transplant
  • Donor must be either unrelated, mismatched up to one antigen/one antigen and one allele or a related, HLA match other than a sibling.

结局指标

主要结局

Engraftment: rates of engraftment, defined as the first day of Absolute Neutrophil Count (ANC) greater than 500 for the first of three consecutive days

时间窗: 1 year

次要结局

  • Severe acute and chronic graft versus host disease (GVHD)(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Timothy Olson

Medical Director, Hematopoietic Stem Cell Transplantation (HSCT) Program

Children's Hospital of Philadelphia

研究点 (2)

Loading locations...

相似试验